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2In 1958 Senning and Elmqvist implanted the first permanent cardiac pacemaker 
(PM) to Arne Larsson, that lived for more than 40 years and died from different 
causes. Since then, the use of cardiac implanted electronic devices (CIEDs) largely 
increased, secondarily to the technological advances, with more patients being 
indicated for implant and a progressively increasing use[1], leading to the 
identification of a new entity, the CIED-detected ‘Atrial High Rate Episodes’ 
(AHREs)[2]. AHREs are episodes of asymptomatic fast atrial tachyarrhythmias that 
cannot be identified through traditional ECG. Usually, AHRE is also referenced as 
‘Subclinical Atrial Fibrillation’ (SCAF)[2]. 
After being identified, has been hypothesized that SCAF could have been associated 
with a higher risk of developing clinical AF and with a higher thromboembolic risk. 
Since then, several studies reported a significant association between SCAF and 
these two clinical events, up to the pivotal ASSERT study[2,3]. In this study, data on 
2451 patients implanted with a CIED showed that SCAF is associated with more 
than 5-fold risk of developing clinical AF and with more than 2-fold risk of having an 
ischemic stroke/systemic embolism, in particular in those patients with a higher 
thromboembolic risk (CHADS2 ≥3)[3]. 
Moreover, a differential risk of stroke was hypothesized according to the AHRE 
burden. In a sub-analysis of the ASSERT trial, was reported that risk of stroke was 
substantially higher in those patients having a SCAF burden ≥24 hours than those 
with a SCAF burden within 5 minutes and 24 hours[4]. Conversely, in a paper by 
Boriani et al., from the SOS AF project (merging data from 3 different studies), it was 





























































3burden[5]. Recently, a meta-analysis showed that risk of stroke progressively 
increased with increasing SCAF duration[6]. On this background, the benefit/risk 
ratio of prescribing oral anticoagulant (OAC) is still unclear[2].
Currently, while some international guidelines do not consider the issue of SCAF 
patients, other ones suggest that on the basis of the evidence available only patients 
with a high risk of stroke or having a high burden of SCAF (≥24 hours) should be 
considered for OAC treatment. Notwithstanding, more data have been advocated to 
clarify if SCAF patients treated with OAC would have a consistent clinical 
benefit[2,7].
In this issue of International Journal of Cardiology, Boriani and colleagues presented 
the results of an international survey organized by the AF-SCREEN International 
Collaboration on diagnosis and management of AHRE[8]. In this study 310 
physicians from Europe (76%), Asia/Oceania (15%) and North America (8%) 
answered to questions designed to understand the knowledge of physicians about 
AHRE, its diagnostic process and the clinical decision-making about OAC 
prescription.
In this interesting survey emerged that while most of the physicians understand that 
the presence of AHRE requires medical attention (96%), a large proportion of 
physicians believed that in patients with very short AHRE duration (between 30 
seconds and 5 minutes) a surface ECG confirmation diagnostic is needed (41% of 
the answers), while 49% would decide to wait for a longer episode detected through 





























































4Conversely, in patients with AHRE lasting from 5 minutes to 24 hours the majority of 
physicians would check the EGMs for further confirmation (74% of the answers).
Regarding the prescription of OAC, a large heterogeneity was found about the 
burden of AHRE in patients with a CHA2DS2-VASc 1 in males or 2 in females 
needed to justify the treatment, with 16% to 27% of physicians that would prescribe 
OAC according to the various burden measurements. In patients with a higher 
thromboembolic risk (CHA2DS2-VASc ≥2 in males or ≥3 in females) 30% of the 
physicians would start OAC irrespective of the AHRE burden, while 34% would start 
OAC only if AHRE lasted ≥5 minutes. Only few physicians (1.9%) wouldn’t start 
OAC. Less uncertainty was found about patients that experienced prior stroke, in 
particular those patients with prior cardioembolic stroke. In these cases, the majority 
of physicians would prescribe OAC irrespective of the AHRE burden. In general, 
most of the physicians considered that in patients with AHRE lasting ≥24 hours 
duration the risk of stroke is similar than in patients with clinical AF[8]. At last, while 
32% of physicians reported that in their opinion there is still insufficient evidence of a 
substantial risk of stroke in patients with AHRE, the large majority stated that while 
there is evidence of a substantial risk of stroke associated with AHRE, there is still a 
lack of evidence on the benefit of OAC[8].
This survey allows us to make some important considerations. On one side, while 
most of physicians consider AHRE a relevant issue, there is large heterogeneity in 
the knowledge related to the diagnostic process. On the other, there is a lot of 
indecision regarding the evaluation of stroke risk in patients with AHRE and the 





























































5clinical scenario for which most of physicians agreed regarding the need of OAC 
prescription, was related to those patients with a previous episode of stroke, 
consistently with the few guidelines recommendations[7]. In general, the survey 
underlined how most of physicians still need to have more evidence about the risk of 
stroke in patients with AHRE and in particular about the clinical benefit of prescribing 
OAC.
While appears clear how more educational initiatives are needed to better inform the 
physicians about the general features of AHRE and the associated risk of stroke, 
evidence coming from two on-going trials, ARTESiA[9] and NOAH–AFNET 6[10], will 
elucidate the impact of OAC in patients with AHRE. In particular, the ARTESiA study 
will provide data about patients with AHRE lasting from 5 minutes to 24 hours, for 
which evidence about a substantial stroke risk is still unclear.
Results of these studies will provide important evidence and clarify what is the most 
appropriate clinical approach for these patients, likely radically changing the 
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